Neglected Disease Licensing: Difference between revisions

From P2P Foundation
Jump to navigation Jump to search
(Created page with ' =Description= Janet Hope: “Equitable Access” and “Neglected Disease Licensing” are twin elements of an open source-inspired proposal for improving access to essent...')
 
 
Line 4: Line 4:
Janet Hope:
Janet Hope:


“Equitable Access” and “[[Neglected Disease Licensing]]” are twin elements of an open source-inspired proposal for improving access to essential medicines, put forward by Amy Kapczynski and colleagues at Yale University. These licensing models explicitly envisage universities as licensors but could be adopted, for example, by other researchers and institutions operating within the TDI framework described above.  Equitable Access licensing aims to improve access to biomedical innovations in low-and middle-income countries. Neglected Disease licensing aims to facilitate research on orphan or neglected diseases."
[[Equitable Access Licensing]] and Neglected Disease Licensing are twin elements of an open source-inspired proposal for improving access to essential medicines, put forward by Amy Kapczynski and colleagues at Yale University. These licensing models explicitly envisage universities as licensors but could be adopted, for example, by other researchers and institutions operating within the TDI framework described above.  Equitable Access licensing aims to improve access to biomedical innovations in low-and middle-income countries. Neglected Disease licensing aims to facilitate research on orphan or neglected diseases."
(http://opensourcebiotech.anu.edu.au/Open_Source_Biotechnology/Practice.html)
(http://opensourcebiotech.anu.edu.au/Open_Source_Biotechnology/Practice.html)


=More Information=
[[Open Source Biotechnology]]
[[Category:Science]]
[[Category:IP]]


=More Information=
=More Information=

Latest revision as of 03:28, 24 August 2009

Description

Janet Hope:

Equitable Access Licensing and Neglected Disease Licensing are twin elements of an open source-inspired proposal for improving access to essential medicines, put forward by Amy Kapczynski and colleagues at Yale University. These licensing models explicitly envisage universities as licensors but could be adopted, for example, by other researchers and institutions operating within the TDI framework described above. Equitable Access licensing aims to improve access to biomedical innovations in low-and middle-income countries. Neglected Disease licensing aims to facilitate research on orphan or neglected diseases." (http://opensourcebiotech.anu.edu.au/Open_Source_Biotechnology/Practice.html)


More Information

Open Source Biotechnology

More Information

Open Source Biotechnology